PANEL NOTES GI SAFETY ISSUES
Merck, Alk-Abello’s ragweed tablet, Ragwitek, glides through FDA panel
By Randy Osborne
Wednesday, January 29, 2014
Qualms about gastrointestinal safety and lack of data in older age groups did not deter the FDA’s Allergenic Products Advisory Committee from giving its nod to recommend approval of Ragwitek, the sublingual ragweed allergy therapy for adults from Merck & Co. Inc. and Alk-Abello A/S.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.